ARP Americas LP Reduces Position in Medifast Inc (NYSE:MED)

ARP Americas LP decreased its stake in shares of Medifast Inc (NYSE:MED) by 26.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,429 shares of the specialty retailer’s stock after selling 871 shares during the period. ARP Americas LP’s holdings in Medifast were worth $337,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC acquired a new position in shares of Medifast during the fourth quarter worth about $26,000. Carroll Financial Associates Inc. acquired a new position in shares of Medifast in the first quarter worth about $38,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Medifast by 53.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 697 shares of the specialty retailer’s stock worth $76,000 after acquiring an additional 244 shares in the last quarter. Toth Financial Advisory Corp lifted its stake in shares of Medifast by 47.6% in the first quarter. Toth Financial Advisory Corp now owns 1,240 shares of the specialty retailer’s stock worth $78,000 after acquiring an additional 400 shares in the last quarter. Finally, Advisor Group Holdings Inc. acquired a new position in shares of Medifast in the first quarter worth about $102,000.

In other news, Director Scott Schlackman sold 3,119 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $107.55, for a total transaction of $335,448.45. Following the completion of the sale, the director now owns 7,555 shares in the company, valued at approximately $812,540.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael C. Macdonald sold 5,000 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $90.74, for a total value of $453,700.00. Following the sale, the director now owns 284,456 shares of the company’s stock, valued at approximately $25,811,537.44. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

Several research analysts recently commented on the company. B. Riley assumed coverage on Medifast in a research note on Thursday, June 25th. They issued a “buy” rating and a $164.00 price target on the stock. DA Davidson boosted their price target on Medifast from $83.00 to $86.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Finally, Zacks Investment Research upgraded Medifast from a “hold” rating to a “strong-buy” rating and set a $110.00 price target on the stock in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Medifast presently has an average rating of “Hold” and a consensus price target of $112.50.

MED stock traded up $1.12 on Friday, reaching $167.13. The company’s stock had a trading volume of 253,108 shares, compared to its average volume of 296,954. Medifast Inc has a 52 week low of $49.03 and a 52 week high of $170.42. The company has a market capitalization of $1.97 billion, a P/E ratio of 26.57 and a beta of 1.27. The firm has a fifty day moving average of $141.85 and a two-hundred day moving average of $100.44.

Medifast (NYSE:MED) last issued its quarterly earnings data on Tuesday, May 5th. The specialty retailer reported $1.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.60. Medifast had a return on equity of 65.66% and a net margin of 10.41%. The business had revenue of $178.46 million during the quarter, compared to analyst estimates of $161.90 million. Research analysts anticipate that Medifast Inc will post 7.61 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 6th. Shareholders of record on Tuesday, June 30th will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, June 29th. This represents a $4.52 dividend on an annualized basis and a yield of 2.70%. Medifast’s dividend payout ratio (DPR) is 75.84%.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.

Featured Article: Municipal Bonds

Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast Inc (NYSE:MED).

Institutional Ownership by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.